With some notable exceptions, e.g. imatinib in the treatment of chronic myeloid leukaemia and vemurafenib BRAF-mutant melanoma, single agent clinical activity with targeted therapies is modest, presumably due to the presence of multiple driver genetic lesions and the rapid development of resistance mechanisms. This evidence concerns the gene BRAF and chronic myelogenous leukemia, BCR-ABL1 positive.